Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.715    0.025 (1.48%)
Bid:
1.50
Ask:
1.93
Spread: 0.43 (28.667%)
Market Cap: £5.93m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

1 Jul 2014 07:00

RNS Number : 9952K
Proteome Sciences PLC
01 July 2014
 



 

 

 

 

 

PRESS RELEASE

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of Roger McDowell as Non-Executive Director

 

1st July, 2014 Proteome Sciences is pleased to announce the appointment of Roger Steven McDowell to the Board of the Company as a non-executive Director with immediate effect.

 

Roger McDowell has a highly successful career as a businessman and entrepreneur. He was Managing Director of Oliver Ashworth for eighteen years before its sale to St. Gobain. He is currently the Chairman or a non-executive director of seven listed companies, namely Avingtrans plc, Servelec Group plc, Renovo plc, Alkane Energy plc, Swallowfield plc, IS Solutions plc and Augean plc. He brings considerable commercial experience with him and is a keen exponent of growing shareholder value.

 

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Roger Steven McDowell, age 60 years, is or has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships Past directorships

Corsair Techinvest Ltd One Advice Group plc

Fineguard Ltd Ultimate Finance Group plc

Augean plc

Disperse Ltd

Dovehoco 201 Ltd

Avingtrans plc

IS Solutions plc

Swallowfield plc

Alkane Energy plc

Renovo plc

Servelec Group plc

 

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies. 

 

At the AGM, held on 30 June 2014, it was announced that Steve Harris, the Chairman, was proposing to retire and he has now formally stepped down as a director.

 

The Board of Proteome Sciences would like to thank him for the considerable contribution and support that he has provided to the Company over the last 20 years, a period in which the Company's outstanding biomarker research has been converted into products, services and commercial revenue. We wish him a long and enjoyable retirement.

 

The CEO, Christopher Pearce, has been appointed Executive Chairman. Dr. Ian Pike remains the Chief Operating Officer.

 

 

- Ends -

 

 

 

 

 

 

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser

Cenkos

Stephen Keys/Callum Davidson

Tel: +44 (0)20 7397 8900

Public Relations

IKON Associates

Adrian Shaw

Tel: +44 (0)1483 271291

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAKBLFXZQFEBBD
Date   Source Headline
20th Aug 20127:00 amRNSRe Agreement
29th Jun 201212:10 pmRNSAGM Statement
7th Jun 20123:10 pmRNSAnnual Financial Report
29th May 20127:00 amRNSFinal Results
30th Apr 20127:00 amRNSTotal Voting Rights
5th Apr 20127:00 amRNSStroke biomarker license to Randox
29th Mar 20125:11 pmRNSBlock Admission Return
28th Mar 20127:00 amRNSCompletion of Alzheimer's Plasma Biomarker Study
19th Mar 201210:00 amRNSEuroHYP EU Grant Award for Stroke
8th Mar 20128:55 amRNSHolding(s) in Company
5th Mar 20127:00 amRNSChange of Adviser
24th Feb 20124:24 pmRNSDirector/PDMR Shareholding
31st Jan 20127:00 amRNSTotal Voting Rights
18th Jan 20127:00 amRNSAdditional Listing
22nd Dec 20117:00 amRNSPromising hits against Alzheimer's Target
24th Nov 20117:00 amRNSNovel In Vitro Assays Developed
8th Nov 20113:39 pmRNSDirector Holdings
7th Oct 20117:00 amRNSBlock Admission Return
30th Sep 20117:00 amRNSInterim Results 2011
11th Aug 20114:35 pmRNSPrice Monitoring Extension
11th Aug 20111:33 pmRNSNotification of Major interest in Shares
9th Aug 20117:00 amRNSProteome Sciences as Preferred Supplier
26th Jul 20117:00 amRNSAppointment of VP Business Development
14th Jul 20117:00 amRNSCollaboration with Buck Institute - biomarket test
7th Jul 20117:00 amRNSCollaboration Agreement
29th Jun 20111:31 pmRNSAGM Statement
28th Jun 20118:12 amRNSDenamic ?6.9m EU Framework Grant
6th Jun 20111:21 pmRNSAnnual Financial Report
27th May 20117:00 amRNSFinal Results
27th May 20117:00 amRNSFinal Results
29th Mar 20117:00 amRNSTakeda Research Contract
28th Mar 20114:38 pmRNSBlocklisting Interim Review
8th Mar 20114:40 pmRNSSecond Price Monitoring Extn
8th Mar 20114:35 pmRNSPrice Monitoring Extension
31st Jan 20117:00 amRNSContract for Biomarker Services with Eisai
10th Jan 20113:39 pmRNSDirector/PDMR Shareholding
23rd Dec 20107:00 amRNSDirectorate Change
20th Dec 20107:00 amRNSResearch Contract
30th Nov 20107:00 amRNSTrading Statement
23rd Nov 201010:30 amRNSBlocklisting Interim Review
23rd Nov 20109:46 amRNSHolding(s) in Company
15th Nov 20107:00 amRNSProteome Sciences form alliance with ICON
14th Oct 20103:00 pmRNSHolding(s) in Company
30th Sep 20107:00 amRNSHalf Yearly Report
28th Sep 20107:00 amRNSStatement re Warranty Claim
23rd Sep 20107:00 amRNSCollaboration with Thermo Fisher
21st Jul 20104:26 pmRNSHolding(s) in Company
13th Jul 20107:00 amRNSProduct Launch
6th Jul 20101:11 pmRNSDirector/PDMR Shareholding
1st Jul 201011:10 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.